CAMBRIDGE, Mass., Feb. 5, 2024
/PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC),
today announced that, effective February 1,
2024, the Compensation Committee of Blueprint Medicines'
Board of Directors granted non-qualified stock options to purchase
an aggregate of 1,717 shares of its common stock and an aggregate
of 858 restricted stock units (RSUs) to three new employees under
Blueprint Medicines' 2020 Inducement Plan.
The 2020 Inducement Plan is used exclusively for the grant of
equity awards to individuals who were not previously an employee or
non-employee director of Blueprint Medicines, as an inducement
material to such individual's entering into employment with
Blueprint Medicines, pursuant to Rule 5635(c)(4) of the Nasdaq
Listing Rules.
The options have an exercise price of $79.88 per share, which is equal to the closing
price of Blueprint Medicines' common stock on February 1, 2024. Each option will vest as to 25%
of the shares underlying such option on the first anniversary of
the grant date and as to an additional 1/48th of the shares
underlying the option monthly thereafter, in each case,
subject to each such employee's continued employment on each
vesting date. Each RSU will vest as to 25% of the shares underlying
the RSU award on the first anniversary of the grant date and as to
an additional 25% of the shares underlying the RSU award annually
thereafter, subject to each such employee's continued employment on
each vesting date. The options and RSUs are subject to the terms
and conditions of Blueprint Medicines' 2020 Inducement Plan, and
the terms and conditions of the stock option and RSU agreement
covering the grant.
About Blueprint Medicines
Blueprint Medicines is a global precision therapy company that
invents life-changing therapies for people with cancer and blood
disorders. Applying an approach that is both precise and agile, we
create medicines that selectively target genetic drivers, with the
goal of staying one step ahead across stages of disease. Since
2011, we have leveraged our research platform, including expertise
in molecular targeting and world-class drug design capabilities, to
rapidly and reproducibly translate science into a broad pipeline of
precision therapies. Today, we have brought our approved medicines
to patients in the United States
and Europe, and we are globally
advancing multiple programs for mast cell disorders, including
systemic mastocytosis and chronic urticaria, breast cancer and
other cancers vulnerable to CDK2 inhibition, as well as EGFR-mutant
lung cancer. For more information, visit
www.BlueprintMedicines.com and follow us on Twitter
(@BlueprintMeds) and LinkedIn.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/blueprint-medicines-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-302053740.html
SOURCE Blueprint Medicines Corporation